Low Molecular Weight Heparin (LMWH) is frequently used in patients with recurrent pregnancy loss, particularly when underlying thrombophilia or unexplained causes are suspected.
The most commonly used LMWH is enoxaparin.
Standard Dosage
- The typical dose for LMWH in recurrent pregnancy loss is 40 mg per day (4000 IU/day of enoxaparin).
- Some studies and clinical practice may use doses ranging from 40 to 80 mg/day, often adjusted according to the patient’s risk status and weight. Tinzaparin (another LMWH) has also been used at equivalent doses (e.g., 3500 IU/day).
- The medication is self-injected subcutaneously, usually started after fetal viability is confirmed (e.g., at 6 weeks of gestation), and continued until delivery or abortion.
Safety and Prophylaxis
LMWH has a good safety profile when used under medical supervision, with rare side effects such as bleeding or thrombocytopenia. It does not cross the placenta, making it a safe choice in pregnancy.
Conclusion
The standard dose for LMWH in the management of recurrent pregnancy loss is 40 mg/day, with some protocols extending up to 80 mg/day based on individual cases. Treatment duration and monitoring should be guided by a fertility or maternal-fetal medicine specialist to ensure optimal safety and success.